



World Biopharm Forum

2023

# Democratisation of Biotherapies: New Manufacturing Modalities & Intensifications

Lady Margaret Hall, University of Oxford  
*21st–23rd June, 2023*

[www.subramanian.org.uk](http://www.subramanian.org.uk)



Sponsors

**SARTORIUS**  
**ABER**

Media Partner

**FL****URISH**

BRAND COMMUNICATIONS

[www.flourishpr.co.uk](http://www.flourishpr.co.uk)





## A warm invitation to come and join us



Following on from our very successful conference “**Continuous Biomanufacturing: Driving value through intensified bioprocessing II**”, we are excited to announce our upcoming 2023 conference “**Democratisation**

**of biotherapies: new manufacturing modalities and intensifications**” to be held at Lady Margaret Hall, University of Oxford, UK on the 21st–23rd June 2023.

We aim for all the delegates and speakers to engage fruitfully in exchanging their knowledge and experience so that they can all advance their work to achieve the goal in increasing the productivity and reducing the cost of the drugs that could be in the reach of people at large.

Over the decades we have witnessed the tremendous growth of biopharmaceutical products, and it's clear that this trend is set to continue. Therefore, this raises the question whether the existing technologies can support and meet demand. One approach is to maintain the status quo, when it comes to manufacturing technology, and continue to invest massive amounts of money in new facilities.

However, this may not be the most efficient way to address the growing demand for biopharmaceuticals at an affordable price.

Instead, we must look to implement new technologies and find smarter ways to meet the growing demand such as product innovation. Industries should fine tune their approach to manufacturing and implement new technologies wherever and whenever possible that allow for operational excellence. This way organisations can distinguish themselves as leaders in the field rather than followers.

World Biopharm Forum 2023 will address some of the advancements under the following theme, equipment, technology, and processes supporting bioprocess intensification. We will hear speakers on intensification enabling technologies upstream and downstream, and on topics such as continuous manufacturing and single use technologies, monitoring and control initiatives, advanced PAT, and digital twin modelling. Plus, speakers will address quality and regulatory topics in cell and gene therapy, vaccines, the design of ATMP facilities, data science and modelling.

*Dr A. Subramanian*

# Wednesday 21st June

2:00pm Registration and canapé reception

2:20pm Welcome: Dr G Subramanian

## DATA SCIENCE AND MODELLING

Chairman: William Whitford DPS Group

2:30pm Using Data To Revolutionize Process Intensification During Cell Line Generation & Process Development

Gerben Zijlstra, Sartorius

3:00pm Digital Transformation Tools To Enable Intensified Bioprocessing

Professor Christoph Herwig,  
Founder Lisalis GmbH; Austria

3:30pm Refreshments and Networking

4:15pm Process Modelling Accelerates Bioprocess Development And Enables Digital Biomanufacturing

Maximilian Krippel, Head of Bioprocess Modeling Consulting, Novasign GmbH, Vienna, Austria | Benedikt Haslinger, Bioprocess Modeling Engineer, Novasign GmbH, Vienna, Austria | Roger Dalmau Diaz, CTO, Novasign GmbH, Vienna, Austria | Mark Duerkop, CEO, Novasign GmbH, Vienna, Austria

4:45pm Biopharma 4.0 For Biologics Manufacturing Under Pandemic Constraints – Digital Twins In Quality-By-Design Based Process Design And Control

Axel Schmidt, Alina Hengelbrock, Alexander Uhl, Jochen Strube | Clausthal University of Technology, 38678 Clausthal-Zellerfeld, Germany

7:30pm Dinner

# Thursday 22nd June

## CONTINUOUS MANUFACTURING: PROCESS CONTROL & ANALYTICS

Chairman: Dr Nick Hutchinson,  
Fujifilm Diosynth Biotechnologies

9:00am Upstream Development Activities That Enable High-Yielding Continuous Manufacturing Processes At 500L Scale

Dr Leon P. Pybus, Fujifilm Diosynth Biotechnologies

9:30am Valorisation Of Spent Cell Culture Media Waste From Bioprocesses

Ciara Lynch & David O'Connell\*, School of Biomolecular & Biomedical Science, BiOrbic Bioeconomy Research Centre, University College Dublin, Ireland

10:00am Developing And Integrating Continuous Technologies For Rapid Delivery Of Cost Effective Biotherapeutics To Patients

Simon Hawdon, UK-CPI, UK

**10:30pm Refreshments and Networking**

**11:00am The Roadmap Towards Continuous Manufacturing And Realtime Release Of Biologics**

*Koen Dierckx, simAbs*

**11:30am Integrated Continuous Processing – The Sustainable Way To Produce Bio-Pharmaceuticals?**

*Bernhard Sissolak: Innovation Management / Bilfinger Life Science GmbH, Salzburg, Austria | Gabriele Recanati, Alois Jungbauer: IBSE / University of Natural Resources and Life Sciences, Vienna, Austria*

### **INTENSIFICATION AT SCALE**

*Chairman: Miriam Monge, Head of Marketing FMT, BPS Marketing, Sartorius*

**Noon Integrated Biomanufacturing As Step Towards Autonomous Production**

*Prof. Alois Jungbauer, Institute of Bioprocess Science and Engineering, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria*

**12:30pm Scalability Of Single-Use Bioreactors In pDNA Production**

*Dr Ir. N.M.G. Oosterhuis; Celltainer Biotech, The Netherlands – DI. G. Schneider; Biotech competence, Austria – Dr Ing. T. Kurt; Celltainer Biosolutions, Germany – Dr. B. Doffek; Biotech competence, Austria*

**1:00pm Lunch**

**2:00pm Scalable mRNA Machine For Regulatory Approval Of Variable Scale Between 1,000 Clinical To 10 Million Manufacturing Scale Doses**

*Alina Hengelbrock, Axel Schmidt, Florian Lukas Vetter, Heribert Helgers, Alex Juckers, Jochen Strube, TU Clausthal, Germany*

**2:30pm Biointelligent Manufacturing As Intensified Bio-Based Systems**

*William Whitford DSP group, USA*

**3:00pm Developing Inline Raman Models For Feed-Back Control Of A High Inoculation Fed Batch Platform Process**

*Colin Jaques, Lonza Biologics*

**3:30pm Refreshments and networking**

### **VIRAL VECTORS AND VACCINES**

*Chairman: Dave Anderson, Director of Sales and Marketing, Aber Instruments Ltd, UK*

**4:15pm Use Of High-Throughput And Doe Tools For Robust Development Of Dsp Technologies For Adeno-Associated Virus (AAV)**

*Paul Cashen, Sartorius*

**4:45pm Scaling Up AAV Purification To Clinical Manufacturing**

*Kathleen Mihlbachler, Rachel Legmann: Repligen Corp. 41 Seyon St Waltham, MA | Corben Davis, Blake Gursky, Ganesh Krishnamoorthy, Frank Agbogbo: Forge Biologics, Grove City, OH*

**5:15pm Intensified Production For A Yellow Fever – Zika Virus Vaccine Candidate**

*Sven Gobel, mpi-magdeburg, Germany*

**7:30pm Gala dinner**

# Friday 23rd June

**9:00am** A Quest For The Best Influenza Producing Clonal Mdck Cell Line: Intensifying By Design Of Experiments, Ambr15 And Bench-Top Bioreactor Cultivations

*Tilia Zinnecker, Udo Reichl, Yvonne Genzel: Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany | Najd Badri, Diogo Araujo, Kristin Thiele: Sartorius Stedim Biotech GmbH, Goettingen, Germany | Udo Reichl: Otto-von-Guericke University, Magdeburg, Germany*

## TECHNOLOGY DEVELOPMENTS

*Chairman: Dr Ing. Kathleen Muhlbacher, Director Process Engineering, Repligen Corporation*

**9:30am** How Can Innovation Change The Access To New Antibody Therapies?

*Christel Fenge is Head of R&D, BioProcess at Cytiva*

**10:00am** Dielectric Spectroscopy And Optical Based Bio-Reflectance Technology Become Mainstream Tools In Pat Applications And Bioprocessing Intensification

*David Anderson, Director of Sales and Marketing, Aber Instruments Ltd, UK*

**10:30am** Refreshments and networking

**11:00am** 2-Stage Continuous Growth-Decoupled Biomolecules Production Using Escherichia Coli – Towards Microbial Small-Footprint Manufacturing

*Juergen Mairhofer. CEO & Co-founder, enGenes Biotech gmbH, Austria*

**11:30am** Expanding Cell Retention Technologies Across Modalities: Making Advanced Therapies Accessible

*John Bonham Carter, Erbi Biosystems, a MilliporeSigma company*

**Noon** Simplifying The Route To Gmp Process Intensification | A Risk Based Approach To Single Use Implementation

*Miriam Monge, Head of Marketing FMT, BPS Marketing, Sartorius*

**12:30pm** CONCLUDING REMARK

*William Whitford*

**1:00pm** Lunch

***All information is correct at the time of print and maybe subject to change.***

# World Biopharm Forum 2023



For bookings, please complete the registration form below and email to [gsub@subramanian.org.uk](mailto:gsub@subramanian.org.uk) or book online at [www.subramanian.org.uk](http://www.subramanian.org.uk)

**FULL NAME** .....

**JOB TITLE** .....

**ORGANISATION** .....

**ADDRESS** .....

.....

**POSTCODE** ..... **COUNTRY** .....

**TELEPHONE** .....

**EMAIL ADDRESS** .....

**ANY SPECIAL REQUIREMENT (DIETARY)** .....

.....

**QUESTIONS OR COMMENTS** .....

.....

## REGISTRATION FEES

Attendance, all meals & accommodation: **£950**


Attendance, all meals & no accommodation: **£800**

## PAYMENT METHOD

Online at [www.subramanian.org.uk](http://www.subramanian.org.uk) or for bank transfer please contact us.

## CANCELLATION

Should you be unable to attend, a substitute delegate is welcomed at no extra charge.



World Biopharm Forum  
**2023**

[www.subramanian.org.uk](http://www.subramanian.org.uk)